Submission of Unaudited financial results for the quarter ended 31st December, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.4 pts more than Nifty Microcap 250 and 2.7 pts more than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Novelix Pharmaceuticals (formerly Trimurthi Limited) reported unaudited Q3FY26 total income of Rs. 4,840.27 lakhs, jumping from just Rs. 530.09 lakhs in Q3FY25 — roughly 9x year-on-year. Nine-month FY26 income stood at Rs. 10,714.52 lakhs versus Rs. 987.35 lakhs in 9MFY25. Net profit after tax for Q3FY26 was Rs. 100.44 lakhs (vs Rs. 14.79 lakhs a year ago), taking 9MFY26 PAT to Rs. 164.46 lakhs compared to a small loss of Rs. 7.65 lakhs in 9MFY25. Basic EPS for the quarter was Rs. 0.58 versus Rs. 0.15 in the year-ago quarter. The auditor (CVS Balachandra Rao & Co.) issued an unmodified limited review report. The dramatic jump reflects the company's pivot to pharmaceutical manufacturing & trading of bulk drugs, following its rename from Trimurthi Limited.
The sharp revenue and profit surge signals a successful business transformation into pharma; however, the very low margins (~2.6% PBT) and dependence on purchases (nearly 99% of revenue) suggest the business is essentially a trading model, which investors should weigh carefully alongside the growth optics.